These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10770533)

  • 1. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients.
    Rubinstein A; Mizrachi Y; Bernstein L; Shliozberg J; Golodner M; Liu GQ; Ochs HD
    AIDS; 2000 Mar; 14(4):F55-62. PubMed ID: 10770533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
    Pakker NG; Kroon ED; Roos MT; Otto SA; Hall D; Wit FW; Hamann D; van der Ende ME; Claessen FA; Kauffmann RH; Koopmans PP; Kroon FP; ten Napel CH; Sprenger HG; Weigel HM; Montaner JS; Lange JM; Reiss P; Schellekens PT; Miedema F
    AIDS; 1999 Feb; 13(2):203-12. PubMed ID: 10202826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization.
    Fogelman I; Davey V; Ochs HD; Elashoff M; Feinberg MB; Mican J; Siegel JP; Sneller M; Lane HC
    J Infect Dis; 2000 Aug; 182(2):435-41. PubMed ID: 10915073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
    Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
    AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
    Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
    AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
    Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
    AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    ;
    AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell changes after combined nucleoside analogue therapy in HIV primary infection.
    Carcelain G; Blanc C; Leibowitch J; Mariot P; Mathez D; Schneider V; Saimot AG; Damond F; Simon F; Debré P; Autran B; Girard PM
    AIDS; 1999 Jun; 13(9):1077-81. PubMed ID: 10397538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.